Credits: Canva
US President Donald Trump recently claimed he had taken an “IQ test,” seemingly mistaking it for a dementia screening exam. Boasting that he achieved a perfect score, he also challenged Democratic representatives Jasmine Crockett and Alexandria Ocasio-Cortez (AOC) to attempt the same test.
Speaking aboard Air Force One, the 79-year-old described the exam as “very hard,” while mocking his opponents as “low IQ” individuals. This mix-up has once again drawn scrutiny to his cognitive health, with experts suggesting the confusion could be a possible sign of dementia.
On Monday (October 27), Trump told reporters that he had aced an intelligence test at Walter Reed Army Medical Center in Washington D.C. According to The New Republic, the test he referred to is likely the Montreal Cognitive Assessment (MoCA), a short 10-minute screening tool designed to detect early signs of dementia or Alzheimer’s disease. Despite this, Trump appeared to treat it as an intelligence measure rather than a diagnostic tool.
During his remarks, the Republican challenged Crockett, 44, and Ocasio-Cortez, 36, to take what he called the “IQ test.” “Let Jasmine go against Trump,” he said. “The first couple of questions are easy: a tiger, an elephant, a giraffe, you know. But when you get up to about five or six, and then 10, 20, 25—they couldn’t answer any of them,” he added.
This is not the first time Donald Trump has spoken about the MoCA test in exaggerated terms or made verbal missteps. Back in 2020, he told Fox News that he was asked “30 to 35 questions” of varying difficulty. “They always show you the first one, like a giraffe, a tiger, or a whale—‘Which one is the whale?’ OK. And then it gets harder and harder,” he said at the time, insisting that others had struggled where he had not.
Observers have long noted that Trump’s speeches often include rambling detours and non-sequiturs. “His speeches are full of non sequiturs,” said historian Kristin Kobes Du Mez of Calvin College, who has compared the speaking styles of Trump and Hillary Clinton. “It’s a completely different style from nearly any other politician you normally see on a big stage.”
Clinical psychologists Dr. Harry Segal and Dr. John Gartner have expressed concern about the president’s psychomotor performance, suggesting that he may be displaying early indicators of dementia. Speaking in a recent episode of their program Shrinking Trump, Dr. Gartner said, “We’ve been observing a clear decline in his motor performance, which aligns with dementia, as it typically involves deterioration across all faculties and functions.”
He added that Trump’s public demeanor, language, and verbal disorganization have become more apparent signs of cognitive changes. According to The Mirror, Trump has also been seen attempting to conceal his hands in public, prompting further speculation about his health.
The recent mix-up between the Montreal Cognitive Assessment and an IQ test, some experts say, could further reinforce these concerns. To better understand this, we spoke with Dr. Neetu Tiwari, MBBS, MD (Psychiatry), Senior Resident at NIIMS Medical College & Hospital.
She explained, “Confusing the nature of the test could be something worth noting. In itself, a single instance of confusion does not amount to a diagnosis of Frontotemporal Dementia (FTD) or any other dementia type. But if this kind of misunderstanding is part of a wider pattern—repeated confusion, new behavioural changes, personality shifts, language difficulties, or problems managing daily tasks—it would justify a full cognitive and neurological assessment. Early detection often relies on observing clusters of symptoms that persist or worsen over time.”
Summing up her view, Dr. Tiwari added that while it is possible for such mislabelling to be a small indicator, it is not strong evidence on its own. “Context matters,” she said. “Age, baseline cognitive ability, education, emotional state, stress, and fatigue all influence mental performance. The responsible next step is to monitor whether other changes are taking place, and if so, to seek a detailed evaluation from a neurologist or neuropsychologist.”
Credits: Canva
Antibiotics have long been considered lifesaving medicines, especially when it comes to treating serious bacterial infections. However, scientists have also known for years that these drugs can disturb the gut microbiome, the vast community of bacteria that live in our digestive system and play an important role in overall health. Now, new research suggests that the impact of some antibiotics on the gut may last far longer than previously believed.
A recent study has found that certain antibiotics may alter the gut microbiome in ways that persist for up to four to eight years after treatment. The findings were reported by scientists from Sweden and published in the journal Nature Medicine. According to the researchers, these long lasting changes may reduce the diversity of bacteria in the gut, which could potentially influence health over time.
The gut microbiome contains hundreds of different species of bacteria that help regulate digestion, immunity, metabolism and even aspects of mental health. A healthy gut microbiome usually has a wide variety of bacterial species. When this diversity decreases, it may make the body more vulnerable to several health conditions.
Scientists have previously linked lower microbial diversity in the gut to problems such as obesity, diabetes and inflammatory bowel disease. Because antibiotics kill bacteria to fight infections, they may also eliminate beneficial microbes along with harmful ones. In some cases, this imbalance may take a long time to recover.
In the new study, researchers identified specific antibiotics that appeared to have the strongest and most lasting effects on gut bacteria. These included clindamycin, fluoroquinolones and flucloxacillin. The study’s lead investigator said that these medications were associated with significant changes in the overall composition of the gut microbiome.
Researchers observed that some bacterial species declined after antibiotic exposure while others increased. This shift altered the balance of the microbial community and was linked to reduced diversity.
To understand the relationship between antibiotics and gut bacteria, the research team analysed data from Sweden’s National Prescribed Drug Register. They then compared this information with gut microbiome samples from 14,979 adults living in Sweden.
The scientists examined the microbiome of people who had been prescribed different antibiotics and compared it with those who had not received any antibiotics during the same period.
Their analysis revealed that some antibiotics had stronger long term effects than others. For instance, penicillin V, one of the most commonly prescribed antibiotics for infections outside hospitals in Sweden, appeared to cause shorter lasting changes in gut bacteria.
However, other antibiotics were linked to more persistent shifts in the microbial ecosystem.
One of the most striking findings of the study was how long the effects could remain visible. According to the researchers, antibiotic use from four to eight years earlier was still associated with differences in a person’s gut microbiome.
Even a single course of certain antibiotics appeared to leave detectable traces years later. While the exact biological mechanisms are still not fully understood, the researchers believe antibiotics may permanently reshape parts of the microbial community in some individuals.
The researchers believe their findings could help guide future decisions about prescribing antibiotics. If two antibiotics are equally effective against an infection, doctors may eventually consider choosing the one that has a weaker impact on the gut microbiome.
Such insights could help balance the need to treat infections while also protecting long term gut health.
To better understand how the microbiome recovers over time, the scientists are now collecting a second set of gut samples from nearly half of the participants involved in the study. This follow up analysis may reveal how quickly the microbiome can recover after antibiotic exposure and which individuals may be more vulnerable to long lasting disruptions.
Credits: Canva
A Food and Drug Administration (FDA) advisory committee on Thursday voted to recommend a new strain of flu in its vaccines for fall. This viral strain of flu is called subclade k.
The World Health Organization (WHO) also suggested that the variant is likely one reason flu vaccines were less effective this year. The Centers for Disease Control and Prevention in its Morbidity and Mortality Weekly Report (MMWR) noted that influenza vaccine effectiveness was 38 per cent to 41 per cent for preventing outpatient visits for children and adolescents and 41 per cent for preventing hospitalization.
For adults, the number was between 22 per cent to 34 per cent against influenza-associated outpatient visits and 30 per cent against influenza-associated hospitalization.
Although the figures were lower than those seen in recent flu seasons, the CDC emphasized that influenza vaccines still offer meaningful protection and continues to recommend vaccination. Last year alone, flu shots helped prevent around 5 million medical visits, 180,000 hospitalizations, and 12,000 deaths.
According to CDC estimates, influenza caused at least 26 million illnesses, 340,000 hospitalizations, and 21,000 deaths between October 1 and February 28.
At the committee meeting, Dr. Lisa Grohskopf, a medical officer in the CDC’s Influenza Division, noted that subclade K is currently the dominant flu variant circulating in the Northern Hemisphere.
However, the University of Minnesota’s Center for Infectious Disease Research and Policy highlighted that flu viruses mutate frequently. This means there is no certainty that the strains chosen now will be the ones circulating in the next flu season. Since vaccine production takes roughly six months, scientists must finalize the formulation as early as February or March.
Arnold Monto, an epidemiologist at the University of Michigan and acting chair of the Vaccines and Related Biological Products Advisory Committee, acknowledged the challenge, noting that selecting the right strains involves “a little bit of science and a little bit of luck,” according to Politico.
Known as the superfly, this is H3N2 'subclade K'. It is a type of seasonal influenza A virus and people have not encountered much of it in the recent years. This is why there is less immunity against it. However, the National Health Service (NHS), UK, has already sent out a 'flu jab SOS' to vulnerable people.
Daniel Elkeles, chief executive of NHS Providers, said that the major concern is that H3N2 is associated with a more severe illness and superflu could be "a very nasty strain of flu". He said that UK could be experiencing a "tidal wave" of illness.
The main strain circulating this winter is a drifted H3N2 variant, which the UKHSA says has left the community with “less natural immunity.” H3N2 strains tend to cause more serious illness in older adults than H1N1 strains and are linked to higher hospitalizations and deaths. This pattern adds further strain to the NHS during the winter months.
Credit: Canva
India has seen a significant rise in the cancer burden, with the cases rising to 1,569,793 in 2025, the government has informed the Parliament.
From more than 1.4 million in 2021, the cancer cases in the country rose to over 144,000 in the last five years, revealed Prataprao Jadhav, Union Minister of State for Health, in a written reply in the Rajya Sabha.
The increase in cases has been consistent:
Similarly, cancer deaths also increased in the country -- 868,588 in 2025 from 789,202 in 2021.
The country reported about 15,000 cancer -related deaths each year:
Jadhav informed that bigger states with large populations have seen a major increase in cancer cases and deaths consistently in the last five years.
States with the highest estimated cancer cases in 2025 include:
Uttar Pradesh - 226,125
Bihar - 118,136 cases
West Bengal - 121,639 cases
Maharashtra - 130,465 cases
Rajasthan - 80,628 cases
States with the highest estimated cancer deaths in 2025 include:
Uttar Pradesh - 125,184 deaths
Bihar - 65,571 deaths
West Bengal - 67,093 deaths
Maharashtra - 71,696 deaths
Rajasthan - 44,402 deaths
Major reasons for the rise in cancer burden include:
“The review provides a critical analysis of the current evidence, summarizing the association of water contamination, including industrial waste, pesticides, and heavy metals, with rectal and colorectal cancer,” Jadhav stated in the Upper House of the Parliament.
Jadhav further informed that the government is tackling the growing burden by expanding cancer care infrastructure across the country.
The Ministry of Health and Family Welfare has implemented the Strengthening of Tertiary Care Cancer Facilities Scheme, which has approved:
Other high-quality comprehensive cancer care facilities in the country include:
© 2024 Bennett, Coleman & Company Limited